Cellaïon

Join our CEO Dr.Jim Phillips' presentation at BioEquity Europe 2024 from 12-14 May in San Sebastian! Request a partnering meeting now: https://lnkd.in/eaw_6uwz 📅May 14 | 11:30 – 11:40 | Room 4+5 | Cell and Gene Therapy: Cellaïon We’ve reached a pivotal stage in the development of Hepastem®, a proprietary, #celltherapy for the treatment of Acute Chronic Liver Failure (ACLF), with data from our Phase 2b trial expected in h2 2024. ACLF has a high mortality rate and no currently approved treatments. Schedule a 1-1 meeting with Jim to discover the potential of Hepastem® to treat and offer hope to 100,000 patients who suffer worldwide from ACLF by reducing inflammation, supporting immunomodulation and promoting the recovery and regeneration of the liver's recipient cells. 🤝Schedule a 1-1 meeting at #BioEquity Europe 2024: https://lnkd.in/eaw_6uwz 🔗Learn how we are redefining liver treatments through cell therapies: www.cellaion.com ✅ Explore the initial efficacy of Hepastem® demonstrated in Phase 2a trials: https://lnkd.in/dATub7Se #Pharma #Biotech #Networking #ACLF #UnmetMedicalNeed

We're pleased to share a positive outcome from the European Medicines Agency (EMA) Scientific Advice procedure, paving a clear path forward to bring our groundbreaking HepaStem® therapy to patients with Acute-on-Chronic Liver Failure (ACLF). The valuable advice we received will assist in shaping our Phase 3 pivotal study, and validates our manufacturing and development strategies. Cellaïon is a clinical stage biotech company developing an innovative, proprietary, cell therapy called HepaStem®, to treat ACLF by reducing inflammation, supporting immunomodulation and promoting the recovery and regeneration of the liver's recipient cells. Highly anticipated data from our Phase 2b trial is expected in H2 2024… 👀 🔗Learn how we are redefining liver treatments through cell therapies: www.cellaion.com ✅ Explore the initial efficacy of Hepastem® demonstrated in Phase 2a trials: https://lnkd.in/dATub7Se #Biotech #LiverDisease #Hepatology #UnmetMedicalNeed #LiverFailure #ATMP #ACLF

World Liver Day is celebrated every year on 19 April to raise awareness and spread knowledge of chronic liver diseases, including Acute-on-Chronic Liver Failure (ACLF) a rapid-onset disease that currently has no approved treatments and is associated with a high mortality rate, up to 75% at 3 months. Our HepaStem® therapy, which is currently in clinical development stage, has the potential to allow recovery and regeneration of the body’s own liver cells and offers hope for the 100,000 patients who suffer from ACLF worldwide. Data from our recently completed phase II clinical trials is expected in H2 2024. 👉 Read the EASL | The Home of Hepatology fact sheet on ACLF: https://ibb.co/sbsG528 🔗 World Liver Day: https://lnkd.in/eKxD3-uF 🧪Learn how we are redefining liver treatments through cell therapies: www.cellaion.com #WorldLiverDay #StepUpForLiverHealth #Biotech #LiverFailure #UnmetMedicalNeed #ACLF

Cellaïon is #hiring a QC Manager! Are you looking for a new QC opportunity in #biotech, do you want to be part of a highly committed team? Check out this job and apply. #job #opportunity #celltherapy #lifesciences #hiringnow #biotechjobs  #QC

We’re delighted to announce a major achievement in our Phase 2b multi-country clinical trial for our HepaStem® therapy (HEP102). The last patient from our 130 study target has been successfully dosed. This milestone marks a decisive step forward in the fight against Acute-on-Chronic Liver Failure (#ACLF). Our innovative treatment provides hope for severely ill patients grappling with this often fatal and rapid-onset disease, for which there is currently no approved treatment. Building on promising results from our Phase 2a data (HEP101), which demonstrated safety and preliminary efficacy of HepaStem®, we are confident in this multi-modal approach to treat ACLF. HepaStem® targets the reduction of inflammation, immunomodulation and promotes the recovery and regeneration of the liver's own cells. With data expected in the second half of 2024, we are eagerly anticipating further insights on HepaStem®'s potential to redefine liver treatments through innovative cell therapies. ✅ Explore the initial efficacy of Hepastem® demonstrated in Phase IIa trials: https://lnkd.in/dATub7Se 🔗 www.cellaion.com #BioTech #LiverDisease #Hepatology

Cellaïon is #hiring! Interested in cell therapy? Passionate in helping patients? Come and join our team. We are looking for a Manufacturing Technician. Are you interested in joining our team? Check out this job!  #Hiring #Biotech #CellTherapy #Manufacturing

On #IWD2024 we are grateful for every member of our entire team, regardless of gender. We are particularly proud of Cellaïon’s talented women making up 48% of our workforce at the company. In addition, our company has a remarkable 55% female representation in the management team, and 44% on our Board of Directors. Today marks International Women's Day 2024, the global day to celebrate the achievements of women around the world. When everyone is included and empowered, we can all rise to our full potential and thrive. We are proud to be developing HepaStem® therapy, now in a Phase IIb multi-country clinical trial, to help severely ill patients affected by Acute-on-Chronic Liver Failure (#ACLF). Collectively achieving a difference in this often fatal and rapid-onset disease, will make a positive impact for women and men. Together at Cellaion, we are pushing boundaries of heathcare innovation to improve outcomes for all. We are Cellaïon. 🔗 https://lnkd.in/dGJVP5Z 🧪Learn how we are redefining liver treatments through cell therapies: www.cellaion.com 👏Pauline De Berdt, Noelia Gordillo, Fabienne Eggermont, Nathalie Adnet, Virginie Trévisanut, Marie-Sophie Martou, Léonie Goeminne, Alexandra Latteux, Astrid van Wessem, Cécile GIROD, Griet Goddemaer, Mégane Derval #BioTech #Liverdisease #hepatology #inspireinclusion #STEM #Hepastem #Cellaion #unmetmedicalneeds #ACLF #research

Today marks Rare Disease Day, and we’re proud be developing transformative medicines for over 100,000 people affected by Acute-on-Chronic Liver Failure (#ACLF) , an often fatal and rapid-onset disease that currently has no approved treatments. We are developing HepaStem® therapy in Phase II clinical trials which has the potential to be used as a ‘bridge’ for severely ill patients awaiting a transplant. 🔗www.rarediseaseday.org 🧪Learn how we are redefining liver treatments through cell therapies: www.cellaion.com #RareDiseaseDay #BioTech #LiverFailure #UnmetMedicalNeed

Our CEO Dr Jim Phillips is presenting at the BioTech Showcase, January 8-10th 2024, in San Francisco. 2:00pm | 9 January | Franciscan 3 Jim will give an update on our lead asset Hepastem®, an allogenic #StemCellTherapy for the treatment of Acute Chronic Liver Failure (ACLF), that has a high mortality rate and no current approved treatments. Hepastem® has multiple modes of action to stop the progression of #ACLF including reducing inflammation, delaying fibrous tissue accumulation, and enabling the recovery and regeneration of the body’s own liver cells. Now is the perfect time to schedule a partnering meeting, with our Phase 2b international clinical trial ‘DHELIVER’ more than 80% recruited and data expected in H2 2024. 🤝: Partnering is open, meet us at #BiotechShowcase 2024: https://lnkd.in/ejhisupD ✅ Initial efficacy of Hepastem® demonstrated in Phase 2a trials: https://lnkd.in/dATub7Se 🔗Learn how we are redefining liver treatments through cell therapies: www.cellaion.com #BioTech #Innovation #ClinicalTrials #LifeScience